176 related articles for article (PubMed ID: 36305094)
1. Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.
Lin X; Lin X; Guo L; Wang Y; Zhang G
Thorac Cancer; 2022 Dec; 13(24):3441-3450. PubMed ID: 36305094
[TBL] [Abstract][Full Text] [Related]
2. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.
Li X; Chen X; Wen L; Wang Y; Chen B; Xue Y; Guo L; Liao N
Thorac Cancer; 2020 Jul; 11(7):1861-1868. PubMed ID: 32412177
[TBL] [Abstract][Full Text] [Related]
3. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
Xiong M; Wang X; Liu D; Xiu B; Zhang Q; Chi W; Goh CW; Zhang L; Chen M; Ren H; Shao ZM; Yang B; Wu J
Cancer Med; 2024 Jan; 13(2):e6955. PubMed ID: 38379328
[TBL] [Abstract][Full Text] [Related]
5. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
[TBL] [Abstract][Full Text] [Related]
6. Concomitant
Lin XY; Guo L; Lin X; Wang Y; Zhang G
J Breast Cancer; 2023 Aug; 26(4):363-377. PubMed ID: 37565929
[TBL] [Abstract][Full Text] [Related]
7. The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer.
Guo L; Chen B; Zhang G; Wang Y; Cao L; Ren C; Wen L; Lin J; Wei G; Liao N
Gene; 2020 Oct; 759():144970. PubMed ID: 32711101
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
Silwal-Pandit L; Vollan HK; Chin SF; Rueda OM; McKinney S; Osako T; Quigley DA; Kristensen VN; Aparicio S; Børresen-Dale AL; Caldas C; Langerød A
Clin Cancer Res; 2014 Jul; 20(13):3569-80. PubMed ID: 24803582
[TBL] [Abstract][Full Text] [Related]
9. Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Li K; Liao N; Chen B; Zhang G; Wang Y; Guo L; Wei G; Jia M; Wen L; Ren C; Cao L; Mok H; Li C; Lin J; Chen X; Zhang Z; Hou T; Li M; Liu J; Balch CM; Liao N
Breast Cancer Res Treat; 2020 Sep; 183(2):321-332. PubMed ID: 32638235
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of
Cao L; Ren C; Zhang G; Li X; Chen B; Li K; Li C; Mok H; Wang Y; Wen L; Jia M; Wei G; Lin J; Liao N
DNA Cell Biol; 2022 May; 41(5):521-538. PubMed ID: 35475703
[No Abstract] [Full Text] [Related]
11. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer.
Zhang L; Sun S; Zhao X; Liu J; Xu Y; Xu L; Song C; Li N; Yu J; Zhao S; Yu P; Fang F; Xie J; Ji X; Yu R; Ou Q; Zhao Z; Li M
Mol Oncol; 2022 Oct; 16(20):3689-3702. PubMed ID: 35971249
[TBL] [Abstract][Full Text] [Related]
13. Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Liu B; Yi Z; Guan Y; Ouyang Q; Li C; Guan X; Lv D; Li L; Zhai J; Qian H; Xu B; Ma F; Zeng Y
Cancer Med; 2022 Jul; 11(14):2767-2778. PubMed ID: 35393784
[TBL] [Abstract][Full Text] [Related]
14. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
15. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations.
Li K; Cao L; Li C; Wu J; Chen B; Zhang G; Li X; Wen L; Jia M; Wei G; Lin J; Li Y; Zhang Y; Mok H; Ren C; Wang Y; Qi X; Guo L; Che Y; Liao N
Cancer Med; 2023 Mar; 12(5):5195-5208. PubMed ID: 36404592
[TBL] [Abstract][Full Text] [Related]
16. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
[TBL] [Abstract][Full Text] [Related]
17. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
18. Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
Chen X; Zhang G; Chen B; Wang Y; Guo L; Cao L; Ren C; Wen L; Liao N
Biomed Pharmacother; 2019 Aug; 116():108997. PubMed ID: 31146111
[TBL] [Abstract][Full Text] [Related]
19. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.
Győrffy B; Bottai G; Lehmann-Che J; Kéri G; Orfi L; Iwamoto T; Desmedt C; Bianchini G; Turner NC; de Thè H; André F; Sotiriou C; Hortobagyi GN; Di Leo A; Pusztai L; Santarpia L
Mol Oncol; 2014 May; 8(3):508-19. PubMed ID: 24462521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
